UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 10-K

(Amendment No. 4)



ANNUAL REPORT PURSUANT TO SECTION 13 OR
15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934



(Mark One)

| | x | ANNUAL REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| | - | ------------------------------------------------------------------------------------



For the fiscal year ended June 30, 2016



Commission file number 000-53239







Cavitation Technologies, Inc.(Exact name of Registrant as Specified in its Charter)



|Nevada                                                         |  | 20-4907818                          
|-------------------------------------------------------------- |  | ------------------------------------
|(State or Other Jurisdiction of Incorporation or Organization) |  | (I.R.S. Employer Identification No.)



10019 CANOGA AVENUE, CHATSWORTH, CALIFORNIA
   91311(Address, including Zip Code, of Principal Executive Offices)



(818) 718-0905(Registrant’s Telephone Number, Including Area Code)



SECURITIES REGISTERED PURSUANT TO SECTION
12(g) OF THE ACT:



|Title of Each Class:           |  | Name of Each Exchange on Which Registered:
|------------------------------ |  | ------------------------------------------
|Common Stock, $0.001 par value |  | Over the Counter (Bulletin Board)         



Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. YES    ̈
    NO   x



Indicate by check mark if the registrant is not required to
file reports pursuant to Section 13 or Section 15(d) of the Act. YES    ̈
    NO   x



Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements
for the past 90 days. YES   x     NO    ̈



Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). YES   x     NO  
 ̈



Indicate by check mark if disclosure of delinquent filers pursuant
to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge,
in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K, or any amendment to this
Form 10-K.  ̈



Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated
filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check
one):



|Large accelerated filer     ̈ | Accelerated filer     ̈ | Non-accelerated filer     ̈(Do not check if a smaller reporting company) | Smaller reporting company    x
|---------------------------- | ---------------------- | ----------------------------------------------------------------------- | ------------------------------



Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act). YES    ̈     NO  
x



State the aggregate market value of the voting and non-voting
common equity held by non-affiliates of the registrant by reference to the price at which the common equity was last sold, or of
the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed
second fiscal quarter: $5,549,057 as of December 31, 2015 based on the closing price of $0.03 per share and 184,968,551 non-affiliate
shares outstanding.



The registrant had 193,997,906 shares of common stock outstanding
on October 13, 2016.



DOCUMENTS INCORPORATED BY REFERENCE:



Items 10, 11, 12, 13 and 14 of Part III incorporate information
by reference from the Form 10-K/A to be filed within 120 days of June 30, 2016.

















CAVITATION TECHNOLOGIES, INC.
FORM 10-K ANNUAL REPORT
FOR THE YEAR ENDED JUNE 30, 2016
TABLE OF CONTENTS



|                                                                                                                     |  | Page
|-------------------------------------------------------------------------------------------------------------------- |  | ----
|PART I                                                                                                               |  |     
|Item 1. Business                                                                                                     |  | 1   
|Item 1A. Risk Factors                                                                                                |  | 3   
|Item 1B. Unresolved Staff Comments                                                                                   |  | 3   
|Item 2. Properties                                                                                                   |  | 3   
|Item 3. Legal Proceedings                                                                                            |  | 3   
|Item 4. Mine Safety Disclosures                                                                                      |  | 4   
|                                                                                                                     |  |     
|PART II                                                                                                              |  |     
|Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |  | 4   
|Item 6. Selected Financial Data                                                                                      |  | 5   
|Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations                        |  | 5   
|Item 7A. Quantitative and Qualitative Disclosures About Market Risk                                                  |  | 9   
|Item 8. Financial Statements and Supplementary Data                                                                  |  | 10  
|Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure                         |  | 27  
|Item 9A. Controls and Procedures                                                                                     |  | 27  
|Item 9B. Other Information                                                                                           |  | 28  
|                                                                                                                     |  |     
|PART III                                                                                                             |  |     
|Item 10. Directors, Executive Officers and Corporate Governance                                                      |  | 29  
|Item 11. Executive Compensation                                                                                      |  | 29  
|Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters              |  | 29  
|Item 13. Certain Relationships and Related Transactions, and Director Independence                                   |  | 29  
|Item 14. Principal Accounting Fees and Services                                                                      |  | 29  
|                                                                                                                     |  |     
|PART IV                                                                                                              |  |     
|Item 15. Exhibits, Financial Statement Schedules                                                                     |  | 30  
|                                                                                                                     |  |     
|Signatures                                                                                                           |  | 31  










EXPLANATORY NOTE



This Amendment
No. 4 on Form 10-K/A hereby amends the Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which Cavitation Technologies,
Inc. (the “Company”) previously filed with the Securities and Exchange Commission (“SEC”) on October 13,
2016, and subsequently amended on December 9, 2016, January 25, 2017 and February 8, 2017. We are filing this amendment solely
for the purpose of correcting a typographical error in the signature date on the date of the Report of Independent Registered Public
Accounting Firm, which was inadvertently dated January 25, 2017 per Amendment No. 2 on Form 10K/A and February 8, 2017, per Amendment
No. 3 on Form 10K/A instead of October 13, 2016. We are also including as Exhibits current certifications required under Section
302 and Section 906 of the Sarbanes-Oxley Act of 2002.



Except as expressly
set forth herein, this Form 10-K/A does not reflect events occurring after the date of the original filing of the Form 10-K or
modify or update any of the other disclosures contained therein in any way. Accordingly, this Form 10-K/A should be read in conjunction
with the original filing on Form 10-K and the Company’s other filings with the SEC.



CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS



This annual report on Form 10-K and the
exhibits attached hereto contain “forward-looking” statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements concern our anticipated results and developments in our operations in future
periods, planned exploration and development of our properties, plans related to our business and matters that may occur in the
future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts
not yet determinable and assumptions of management. We use words like “expects,” “believes,” “intends,”
“anticipates,” “plans,” “targets,” “projects” or “estimates” in this
annual report. When used, these words and other, similar words and phrases or statements that an event, action or result “will,”
“may,” “could,” or “should” result, occur, be taken or be achieved, identify “forward-looking”
statements. Such forward-looking statements are subject to certain risks and uncertainties, both known and unknown, and assumptions.



Management has included projections and
estimates in this annual report, which are based primarily on management’s experience in the industry, assessments of our
results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with
the Securities and Exchange Commission or otherwise publicly available. We caution readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking
statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or
unanticipated events, except as required by law. We qualify all of the forward-looking statements contained in this annual report
by the foregoing cautionary statements.










PART I



ITEM 1.  BUSINESS



Cavitation Technologies, Inc. (referred
to herein, unless otherwise indicated, as “the Company,” “CTi,” “we,” “us,” and
“our”) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. We have developed, patented,
and commercialized proprietary technology that may be used in liquid processing applications. Our patented Nano Reactor®
is the critical component of our CTi Nano Neutralization® System which has been shown to reduce operating costs and
increase yields in refining vegetable oils. We have 3 issued patents for device/apparatus and another 8 for processes in the US,
as well as 1 patent issued for process in Singapore. We have also filed 6 patent applications in the US and another 9 internationally
to employ our proprietary technology in applications including vegetable and oil refining, waste water treatment, algae oil extraction,
and alcoholic beverage enhancement.



In addition, we have commercialized our
CTi Nano Neutralization® System in the refining process of certain vegetable oils which has proven to reduce costs and
increase yields for our customers.



Vegetable Oil Refining



Our first commercial application for our
technology is the CTi Nano Neutralization® System . Our environmentally friendly process has been shown to reduce refining
costs, increase oil yield, and limit the amount of chemical additives used in chemical refining vegetables oils. This patented
process (US Patent # 8,911,808) is designed to be incorporated into new and existing soybean, rapeseed, and canola oil chemical
refineries.



Our first pilot test of our CTi NANO
Neutralization System was conducted in 2010 at Carolina Soya, a 200 metric ton/day crude soy oil refining plant in Estill,
South Carolina. Our second system, which became operational in fiscal 2011, is a 450 metric tons per day plant that has been in
continuous operation since. We have successfully shipped over 24 systems both domestically and abroad.



The global demand for vegetable oils has
grown consistently at a rate of about 5.5% p.a. from 84.5 million metric tons in 1999 to over 175 million metric tons in 2015-2016
(https://www.statista.com/statistics/263937/vegetable-oils-global-consumption/). It is also a highly competitive commodity market
in which the lowest-cost producer has the advantage.



Desmet Ballestra Agreement



On May 14, 2012 we signed a global R
and D, Marketing and Technology License Agreement with Desmet Ballestra Group s.a. (Desmet), a Belgian company that is actively
marketing the NANO Neutralization System, the key component of which is the Company’s reactor to soybean and other
vegetable oil refiners. The Agreement provided Desmet (licensee) a limited, exclusive license and right to develop, design and
supply Nano Reactor® systems which incorporate Nano Reactor® devices on a global basis but was limited to oils and fats
and oleo chemical applications. We, as the licensor, remained the owner of the current patents and patent applications but Desmet
would be the co-owner of any new process patent applications jointly developed. Desmet provided, under certain conditions, limited
monthly advance payments of $125,000 against future sales to us through May 2015. This Agreement terminated May 2015.



On January 22, 2016, we signed a similar
three-year agreement with Desmet effective August 1, 2015. As part of the agreement, Desmet is to provide, under certain conditions,
limited monthly advance payments of $50,000 against future sales to us. The agreement may be terminated by Desmet every August
1 should Desmet and its affiliates fail to convert a minimum of six Nano Reactors System to sold status during the period of June
1 to May 31. The agreement may also be terminated in case were to lose its rights under the patents and patent applications being
used in our CTi NANO Neutralization System.



Desmet, together with its affiliates, is
a global engineering and equipment supply firm engaged in the development, design and supply of process equipment for oils and
fats processing facilities including vegetable oil refining, biofuel, oleo chemical, seed crushing, surfactant and detergent markets.
Desmet supplies these markets with services based on the latest globally sourced technologies. Desmet has relationships with major
refiners globally A significant portion of global vegetable oil refineries include major refiners such as Archer Daniels Midland
Company, Cargill, Inc. and Bunge Limited. Desmet has more than 40 sales representatives selling in North America, South America,
Europe, and Asia. Since its founding in 1946, Desmet reports that it has built a global network that includes 1,300 employees,
17 global and 8 representative offices, and more than 5,700 lines in a variety of applications. Desmet operates a separate division
for each of the above markets and the Desmet Oils & Fats division has supplied small and large plants to approximately 1,700
oil millers in 150 countries, covering over 6,000 process sections. We have developed a relationship with the North American arm
of Desmet which operates in each of these markets and provides us with other potential opportunities such as palm oil refining.



1







We and Desmet have worked together to determine
the appropriate sales approach and installation process. Our CTi Nano Neutralization System is designed to be used as an add-on
process to an existing neutralization system within soybean and other vegetable oil refineries. Desmet is now focused on marketing
our CTi’s Nano Neutralization® System to vegetable oil refiners to help them increase profits through cost savings
and improved oil yields. Desmet purchases our CTi Nano Neutralization Reactor Systems from us and installs them at the refinery
as part of an integrated neutralization system. Based on successful commercial implementations, Desmet guarantees minimum economic
benefits to a facility that installs our CTi Nano Neutralization® Systems . We are therefore substantially dependent
on Desmet to identify prospects, complete sales contracts, install the system and manage relationships with end-users. We focus
on developing additional Nano Reactor® applications and managing the intellectual property issues associated with new developments.



Customers/ Dependence on One Customer



We continue to sell our Nano Reactors and
technology only to one customer, Desmet and they are responsible for installing and servicing the systems. All of our revenue for
the fiscal year ended June 30, 2016 was derived from sales of products to Desmet.



Sources and availability of raw materials
and the names of principal suppliers



We have historically sourced reactor components
from various domestic and international suppliers including Canyon Engineering, EA365 Management, NH Management., Inc. and Strategic
IR with whom we have no long term contracts, agreements, or commitments. They provide parts as directed. We believe it would take
approximately 60 days to find a new supplier, if necessary.



Competition



Our competitors who sell equipment and
engineering services for the vegetable oil refining business are a myriad of companies both large and small that provide equipment
and technology to oil refiners. These include known companies that have longer operating histories, more experience, and stronger
financial capabilities. Competitors include Westfalia, Alfa Laval, and Crown Iron Works as well as many firms that provide advice
and services to small and regional firms. In addition, Arisdyne Systems, a designer of cavitation devices, is marketing a system
using similar technology. The vegetable oil refining business is a highly competitive commodity market in which where the lowest-cost
producer has the advantage. We intend to compete by offering solutions that help our clients remain or become a low-cost producer.
Because the industry in which we compete has had limited new technology introduced in the last 50 years, we believe our CTi
Nano Neutralization® Systems provide a unique opportunity for refiners to increase margins. We seek to differentiate ourselves
by offering solutions based on our proprietary and patented designs, processes, and applications to help our clients described
in our issued and patent pending applications. We compete by offering solutions that we believe can reduce operating expenses and
increase yield vis-à-vis their current applied technology.



Patents



Our Cavitation Generator patent
was issued during fiscal 2011. In addition, we have a patent for our Multi-State Cavitation Device that was issued August
22, 2011. In the fiscal 2014 we received approvals for another 3 patents in the US for various processes. During fiscal years 2015
and 2016, we also received approvals in the US for another 5 patents for various processes and 1 for another device/apparatus.
We also received 1 patent approval for its device in Singapore.



We also have 6 US and 9 PCT/ international
patent applications pending which apply to the design of our reactor and the processes related thereto. We filed a number of process
patent applications incorporating these patented devices for processing fluids in vegetable oil refining, waste water treatment,
algae oil extraction, and alcoholic beverage enhancement. We received comments from the United States Patent and Trademark Office
with regard to our Method for Cavitation-Assisted Refining, Degumming, and Dewaxing of Oil and Fat, and we responded. We also received
a second round of comments and are responding to those as well. There is no assurance that our patents pending will be ultimately
issued.



We believe our technology can be applied
to other liquid processing industries where there is a need to solve environmental problems, reduce operating costs, and/or improve
quality and yield. Our issued and allowed patents and pending patents support potential applications of the Company’s proprietary
technology in markets which include, but are not limited to, vegetable oils refining, renewable fuel production, alcoholic beverage
enhancement, water purification, and algae oil extraction. In addition, we believe our proprietary technology may also be applied
to fuel mixing and crude oil refining. During fiscal 2011, we received the “CE Marking” certification which allows
us to market our systems in the European Union. Our success will depend in part on our ability to obtain patents, maintain trade
secrets, and operate without infringing on the proprietary rights of others both in the United States and other countries. There
can be no assurances that patents issued to us will not be challenged, invalidated, or circumvented, or that the rights granted
hereunder will provide proprietary protection or competitive advantage to us. We plan to continue to invest in R&D and file
for new and improved patents.



2







Royalty Agreements



On July 1, 2008, our wholly owned subsidiary
entered into Patent Assignment Agreements with two parties, our President as well as our former Chief Executive Officer (CEO) and
current Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation processes invented
by the President and former CEO/current Technology Senior Manager have been assigned to the subsidiary.  In exchange,
that subsidiary agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/current Technology Senior
Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently
assumed by us on May 13, 2010 from our subsidiary. Our former CEO/current Technology Senior Manager and President both waived
their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30,
2016.



On April 30, 2008 and as amended on November
22, 2010, our wholly owned subsidiary entered into an employment agreement with its former Director of Chemical and Analytical
Department (the “Inventor”) to pay, in the first year, an amount equal to 5% of actual gross revenue received by us
on any patent for which the Inventor was a legally named inventor, and, in each subsequent year, 3% of actual gross revenue received
by us on any such patent. Since entering into that employment agreement, and during the term of this employment agreement, we have
not received any revenue on any patents for which the Inventor was a legally named inventor.



Governmental Approval and Regulations
and Environmental Compliance



Due to the nature of our products, we have
incurred no costs with respect to environmental compliance with federal, state, and local laws. To our knowledge, our products
do not require governmental approval, and we do not foresee that governmental regulations will have a material impact on our business.



Employees



On June 30, 2016 we had four full-time
employees and had engaged several consultants and independent contractors over the past year. Members of our staff and technical
team are comprised of experienced professionals who are chemists, civil-, chemical-, and mechanical engineers with expertise in
hydrodynamic cavitation, Nano technology, and water treatment. These individuals hold degrees in Civil, Chemical, and Mechanical
Engineering.



Research and Development Expenditures



During the fiscal years ended June 30,
2016 and 2015, we spent $29,371 and $22,310 of research and development activities.



ITEM 1A.  RISK FACTORS



Not applicable for smaller reporting companies.



ITEM 1B.  UNRESOLVED STAFF COMMENTS



None.



ITEM 2.  PROPERTIES



Our corporate headquarters are located
in Chatsworth, California. This approximate 5,000 square foot facility includes office space and an area to conduct research and
development.  Our lease agreement for this space will end on February 1, 2018.  Our monthly rent payments are
$4,929.10. We do not anticipate any material difficulties with the renewal of our rental agreement when it expires or in securing
replacement facilities on commercially reasonable terms.



ITEM 3.  LEGAL PROCEEDINGS



We are involved in certain legal proceedings
that arise from time to time in the ordinary course of our business. As of June 30, 2016, we were a party to legal proceedings
related to claims for payment that are currently accrued for in its financial statements. Except for income tax contingencies,
our record accruals for contingencies to the extent that management concludes that the occurrence is probable and that the related
amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. Material
legal proceedings that are currently pending are as follows:



3







| | a. | On September 5 2013, a former
employee who was also a former Director filed an administrative Complaint for approximately $179,000 in unpaid wages, plus penalties
and interest, with the California Labor Commissioner’s Office (CLCO).  In January 2016, the CLCO ruled in favor of
us and dismissed the case. As a result of this ruling, our obligation to the former employee and former Director only amounted
to approximately $134,000 which was accrued in prior periods and included as part of Accrued Payroll and payroll taxes due to
officers in the accompanying balance sheet.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



In February
2016, the same former employee and who is also a former Director has now appealed this ruling to the Los Angeles County Superior
Court.  In addition to defending ourselves, we also filed a cross-complaint against the former employee and former Director
for breach of contract and breach of fiduciary duty as a Director.  Trial is currently scheduled to begin in 2017. Based upon
available information at this very early stage of litigation, Management believes the likelihood of material loss resulting from
this lawsuit to be remote.



| | b. | We have several patents issued by the US Patent Office with regards to the use and efficacy of its Nano Reactors. In August 2015, a competitor, Arisdyne System filed a complaint challenging the patentability of certain claims of our Patent No. 8,911,808 B2 or Patent 808. Patent 808 is currently being used in the reactors purchased by our distributor, Desmet. In January 2016, we and Arisdyne System terminated the complaint with no monetary compensation paid and agreed to a mutual release of further liabilities associated with the use of aforementioned patents and technologies.
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



ITEM 4.  MINE SAFETY DISCLOSURES



Not applicable.



PART II



ITEM 5.  MARKET FOR REGISTRANT’S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES



Common Stock



Our Common Stock is traded on the OTCQB
Market under the symbol CVAT. The following table sets forth the high and low price per share based on the closing price of our
Common Stock for the periods indicated.



|            |  |                |  | HIGH |      |  | LOW | 
|----------- |  | -------------- |  | ---- | ---- |  | --- | 
|            |  |                |  |      |      |  |     | 
|Fiscal 2015 |  | First Quarter  |  | $    | 0.10 |  |     | 
|            |  | Second Quarter |  |      | 0.08 |  |     | 
|            |  | Third Quarter  |  |      | 0.07 |  |     | 
|            |  | Fourth Quarter |  |      | 0.06 |  |     | 



|            |  |                |  | HIGH |      |  | LOW | 
|----------- |  | -------------- |  | ---- | ---- |  | --- | 
|            |  |                |  |      |      |  |     | 
|Fiscal 2016 |  | First Quarter  |  | $    | 0.06 |  |     | 
|            |  | Second Quarter |  |      | 0.03 |  |     | 
|            |  | Third Quarter  |  |      | 0.04 |  |     | 
|            |  | Fourth Quarter |  |      | 0.04 |  |     | 



We became a public company through a share
exchange that was effected in October 2008. The first day of public trading of our stock was November 11, 2008. Since our fiscal
year end was changed to June 30, public trading of our stock began in the second quarter of fiscal 2009. As of September 28, 2016,
there were approximately 1,100 holders of record of our Common Stock. This does not reflect the number of persons or entities who
hold stock in nominee or “street” name through various brokerage firms.



4







Dividend Policy



We have neither declared nor paid any dividends
on our Common Stock in the preceding two fiscal years. We currently intend to retain future earnings to fund ongoing operations
and finance the growth and development of our business and, therefore, do not anticipate declaring or paying cash dividends on
our Common Stock for the foreseeable future. Any future decision to declare or pay dividends will be at the discretion of the Board
of Directors and will be dependent upon our financial condition, results of operations, capital requirements, and such other factors
as the Board of Directors deems relevant. In addition, certain of our debt facilities contain restrictions on the declaration and
payment of dividends.



Securities Authorized for Issuance under
Equity Compensation Plans



None.



Recent Sales of Equity Securities and
Use of Proceeds



We did not sell any equity securities during
the year ended June 30, 2016 in transactions that were not registered under the Securities Act of 1933, as amended, other than
as previously disclosed in our filings with the Securities and Exchange Commission.



Issuer Purchases of Equity Securities



There were no issuer purchases of equity
securities during the year ended June 30, 2016.



ITEM 6.   SELECTED FINANCIAL
DATA



Not applicable for smaller reporting companies.



ITEM 7.  MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS



The following discussion and analysis
should be read in conjunction with our financial statements and the related notes. This discussion contains forward-looking statements
based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions.
Its actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements.



Overview of Our Business



Hydrodynamic Technology, Inc. was incorporated
on January 29, 2007 as a California corporation. It is a wholly owned subsidiary of Cavitation Technologies, Inc., a Nevada corporation
originally incorporated under the name Bio Energy, Inc. We are a process and product development firm that has developed, patented,
and commercialized environmentally friendly technology based systems that are designed to serve large, growing, global markets
such as vegetable oil refining, renewable fuels, water treatment, algae oil extraction, water-oil emulsions and crude oil yield
enhancement.  Our systems are designed to process industrial liquids at a lower cost and higher yield than conventional
technology.



We have developed, patented, and commercialized
proprietary technology that can be used for processing of industrial fluids. Our patented Nano Reactor® is the critical
components of the CTi Nano Neutralization® System which has been shown to reduce operating costs and increase yields
in processing oils and fats. CTi has five issued patents relating to our Nano Reactor® systems and has filed several
national and international patents to employ its proprietary technology in applications including vegetable and crude oil refining,
waste water treatment, algae oil extraction, and alcoholic beverage enhancement.



During the year ended June 30, 2016, we
recorded revenue of $1,798,217. Our income from operations in 2016 was $432,780 and cumulative net cash used in operating activities
was $759,604, which was funded largely by advances received from a strategic partner and distributor, Desmet Ballestra Group (Desmet)
in the amount of $500,000 (which is reported as Advances from the Distributor Payable in our financial statements) as well as cash
reserves and additional cash receipts from Desmet under the January 2016 agreement in the amount of $113,767.



5







Management’s Plan of Operation



We are engaged in merchandising our CTi
NanoNeutralization System which is designed to help refine vegetable oils such as soybean, canola, and rapeseed.  Our
near term goal is to continue to merchandise our systems through our partner, Desmet Ballestra.



We have a working capital deficiency of
$791,252 and a stockholders’ deficit of $642,775 as of June 30, 2016. The accompanying financial statements have been prepared
in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.



Management’s plan is to generate
income from operations by licensing our technology globally through our strategic partner, Desmet Ballestra Group (Desmet). Desmet
is obligated to provide us with monthly advances of $50,000 against future sales under an agreement that may be terminated on each
August 1 under certain circumstances. During the year ended June 30, 2016, advances received from Desmet amounted to $500,000.
These funds service operational expenses on a monthly basis. The agreement may be terminated by Desmet every August 1 should Desmet
and its affiliates fail to convert a minimum of six Nano Reactors System to sold status during the period of June 1 to May 31.
The agreement may also be terminated in case the Company loses ownership of patents and patent applications being used in our CTi
Nano Neutralization System.



In addition to these advances, we anticipate
that we will need additional funding, and we will attempt to raise additional debt and/or equity financing to fund operations and
to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient
amounts necessary to meet the Company’s needs, or that the Company will be able to meet its future contractual obligations.
Should management fail to obtain such financing, the Company may curtail its operations. For a more detailed discussion of our
plan, please review to Part I, Item 1, Business . Management estimates that cash on hand together with advances from Desmet
will allow the Company to operate beyond fiscal 2018.



The accompanying consolidated financial
statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets
or the amounts and classification of liabilities that may result from an inability of the Company to continue as a going concern.
As a result of the aforementioned factors, our independent auditors, in their report on our audited financial statements as of
and for the year ended June 30, 2016, expressed substantial doubt about our ability to continue as a going concern.



Critical Accounting Policies and Revenue
Recognition



Our discussion and analysis of our financial
condition and results of operations are based upon our consolidated financial statements which have been prepared in accordance
with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial
statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities
and the reported amounts of revenues and expenses. The accounting policies and estimates described below are those we consider
most critical in preparing its consolidated financial statements. The following is a review of the accounting policies and estimates
that include significant judgments made by management using information available at the time the estimates are made. However,
these estimates could change materially if different information or assumptions were used instead.



Note 3 to our consolidated financial statements
includes a summary of significant accounting policies, estimates, and methods used in the preparation of our financial statements.
Accounting estimates are an integral part of the preparation of financial statements and are based on judgments by management using
its knowledge and experience about the past and current events and assumptions regarding future events, all of which we consider
to be reasonable. These judgments and estimates reflect the effects of matters that are inherently uncertain and that affect the
carrying value of our assets and liabilities, the disclosure of contingent liabilities and reported amounts of expenses during
the reporting period.



Revenue Recognition



Revenue from the sale of our Nano Reactor®
systems is recognized when persuasive evidence of an agreement exists; shipment has occurred, including transfer of title and
risk of loss for product sales, or services have been rendered for service revenues; the price to the buyer is fixed or determinable;
and collectability is reasonably assured.



We are also entitled to certain non-refundable
profit share from our distributor from the sale of the reactors. Pursuant to the May 2012 agreement with our distributor, the profit
share was fixed and determinable at the time of shipment, and as such, recorded upon shipment and acceptance of the reactors by
the distributor. Pursuant to the January 2016 agreement with our distributor, the profit share is not fixed at the time of delivery,
and as such, revenue will be recognized when the profit share is fixed and determinable, which will generally be upon delivery
of our CTi Nano Neutralization System by the distributor to its customer.



6







Recoverability of Intangible and Long
Lived Assets



Management believes that the accounting
estimate related to the recoverability of its intangible and long-lived assets is a “critical accounting estimate”
because significant changes in the assumptions used to develop the estimates could materially affect key financial measures, including
net income and non-current assets.



Testing intangible and long-lived assets
for impairment involves a high degree of judgment due to the assumptions that underlie the undiscounted cash flows analysis. In
accordance with ASC 350-30, we evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that
the net book value may not be recoverable. When such factors and circumstances exist, we compare the projected undiscounted future
cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying
amount. Impairment, if any, is based on the excess of the carrying amount over the fair value based on market value when available
or discounted expected cash flows of those assets and is recorded in the period in which the determination is made. Management
believes there is no impairment of its long-lived assets. There can be no assurance, however, that market conditions will not change
or demand for our products under development will continue. Either of these could result in future impairment of long-lived assets.



Share-Based Compensation



We periodically issues stock options and
warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for
stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting
Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. We account
for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial
Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either
a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity
instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line
basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately
vested and the total stock-based compensation charge is recorded in the period of the measurement date.



Determining the fair value of share-based
awards at the measurement date requires judgment, including estimating the expected term that stock options and warrants will be
outstanding prior to exercise, the associated volatility, and the expected dividends. We estimate the fair value of options granted
using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period the options are
expected to be outstanding and has been determined based on historical exercise experience. Expected stock price volatility is
based on the historical volatility of our stock for a period approximating the expected life, and the risk-free interest rate is
based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. Judgment is also required
in estimating the amount of share-based awards that will be forfeited prior to vesting. We believe that these assumptions are “critical
accounting estimates” because significant changes in the assumptions used to develop the estimates could materially affect
key financial measures including net income (loss).



Recent Accounting Pronouncements



See Note 3 of the financial statements
for discussion of recent accounting pronouncements.



7







Results of Operations



Below is summary comparing fiscal 2016
and fiscal 2015.



|                                    |  | For the Years Ended |           |  |      |   |            |          | 
|----------------------------------- |  | ------------------- | --------- |  | ---- | - | ---------- | -------- | 
|                                    |  | June 30,            |           |  |      |   |            |          | 
|                                    |  | 2016                |           |  | 2015 |   |            | $ Change | 
|                                    |  |                     |           |  |      |   |            |          | 
|Revenue                             |  | $                   | 1,798,217 |  |      | $ | 489,255    |          | 
|Cost of revenue                     |  |                     | 121,505   |  |      |   | 73,253     |          | 
|Gross profit                        |  |                     | 1,676,712 |  |      |   | 416,002    |          | 
|                                    |  |                     |           |  |      |   |            |          | 
|General and administrative expenses |  |                     | 1,214,561 |  |      |   | 1,772,618  |          | 
|Research and development expenses   |  |                     | 29,371    |  |      |   | 22,310     |          | 
|Total operating expenses            |  |                     | 1,243,932 |  |      |   | 1,794,928  |          | 
|Income (loss) from operations       |  |                     | 432,780   |  |      |   | (1,378,926 | )        | 
|Interest expense and other          |  |                     | -         |  |      |   | -          |          | 
|Net income (loss)                   |  | $                   | 432,780   |  |      | $ | (1,378,926 | )        | 



Revenue



During the year ended June 30, 2016, revenue
increased 267% to $1,798,217 and was derived from the sale of four of our CTi Nano Neutralization Systems and fifteen reactor
lines (a total of 45 reactors) delivered to Desmet as part of the revised agreement entered into in January 2016. During the year
ended June 30, 2015, revenue of $489,255 was derived largely from the sale of three of our CTi Nano Neutralization Systems
..



Operating Expenses



Operating expenses for fiscal 2016 amounted
to $1,243,932 versus $1,794,928 fiscal 2015, a decrease of $550,996 or 31%. The decrease was mostly attributable to a 32% reduction
in General and administrative (G&A) expenses, which in turn was mostly affected by a reduction in non-cash compensation for
officers and consultants. Non-cash expense items such as amortization and depreciation expense of $60,126, and inventory valuation
loss of $18,792 among others, amounted to a small proportion of G&A expenses, with major expense categories being salaries
and payroll taxes of approximately $505,000, professional fees of approximately $174,000, various insurance policies amounting
to $96,333 and travel, insurance and marketing services fees. Research and development (R&D) expense increased by $7,062 for
the year ended June 30, 2016 due to reactor systems tested in fiscal 2016 and as we tended to rely less on our partner, Desmet
Ballestra, for R&D.



In fiscal 2015, non-cash expense items
such as share based compensation of $64,080 and consulting expense of $245,375, together with patent amortization and depreciation
expense of $154,554, among others, amounted to just over 25% of G&A expenses, with other major expense categories being salaries
and payroll taxes of approximately $476,000, professional fees of approximately $130,000, and travel, insurance and marketing services
fees being some of the other major cash expense items.



Our reported Net Income in fiscal 2016
was $432,780 as compared to a Net Loss of $1,378,926 in fiscal 2015.



Liquidity and Capital Resources



During the fiscal year ended on June 30,
2016, cash used in operating activities of $759,604 and net investing activities (purchases of inventory) of $61,565 were financed
with cash reserves and receipts of cash as both advances and sales from our partner, Desmet Ballestra.



During the fiscal year ended June 30, 2015,
proceeds from sale of 5.2 million shares of common stock amounted to $375,498. These proceeds financed operating activities of
$100,691 and investing activities resulting in purchase of equipment of $22,750. These activities resulted in net increase in cash
of $252,057.



The accompanying consolidated financial
statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the
Company as a going concern.  During the year ended June 30, 2016, we utilized $759,604 of cash in operations. As of June
30, 2016, we had a working capital deficiency of $791,252 and a stockholders’ deficit of $642,775.   We have also
been dependent on certain aspects of its funding from a technology agreement with a distributor. These factors, among others, raise
substantial doubt about our ability to continue as a going concern.



8







The accompanying consolidated financial
statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets
or the amounts and classification of liabilities that may result from an inability of us to continue as a going concern. In addition,
our independent registered public accounting firm, in its report on our June 30, 2016 consolidated financial statements, has raised
substantial doubt about our ability to continue as a going concern. Management’s plan is to generate income from operations
by continuing to license its technology globally through our strategic partner with the Desmet Ballestra Group (Desmet). Pursuant
to a R&D, Marketing and Technology License agreement with Desmet that was signed in January 2016, Desmet has provided us monthly
advances of $50,000 which started in January of 2016 and are expected to continue through August 2018 but can be terminated on
each August 1 under certain circumstances. These advances will be applied against future sales to Desmet. During the year ended
June 30, 2016 advances received from Desmet amounted to $500,000.



We will also attempt to raise additional
debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing
will be available in the future or obtained in sufficient amounts necessary to meet our needs, that we will be able to achieve
profitable operations or that we will be able to meet our future contractual obligations. Should management fail to obtain such
financing, we may curtail its operations.



Sources and Uses of Cash



During the fiscal year ended June 30, 2016,
net cash used in operating activities amounted to $759,604, an increase over fiscal 2015 of almost $658,913. During the year ended
June 30, 2016 we received gross proceeds of $500,000 in advances against future sales from our partner, Desmet Ballestra, and $113,767
as payment for reactors. This cash was used largely to pay operating costs, professional service providers such as auditors and
accountants, acquire new inventory, pay management salaries and to pay travel and insurance expenses. The Agreement with Desmet
expired in May 2015 and the new agreement was signed in January of 2016 which provides for monthly advances of $50,000 to us. 
During fiscal 2015, net cash used in operating activities amounted to $100,691 and we received gross proceeds of $1,375,000 in
advances against future sales from our partner, Desmet Ballestra.



Net cash used in investing activities for
property, plant, and equipment during fiscal 2016 and fiscal 2015 amounted to $61,565 and $22,750 respectively.



We did not conduct any financing activities
in the current fiscal year ended June 30, 2016. For the fiscal year ended June 30, 2015 net cash provided by financing activities
of $375,498 consisted of cash received as a result of the sale of our common stock. These proceeds financed the operating and investing
activities and provided net cash increase for future operations.



Off-balance Sheet Arrangements



We have no off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on its financial condition, revenues or expenses, results
of operations, liquidity, capital expenditures or capital resources.



ITEM 7A.  Quantitative and
Qualitative Disclosures about Market Risk.



Not applicable for Smaller Reporting Companies.



9







ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM



To the Board of Directors
Cavitation Technologies, Inc.
Los Angeles, CA



We have audited the accompanying consolidated
balance sheets of Cavitation Technologies, Inc. (the “Company”) as of June 30, 2016 and 2015 and the related consolidated
statements of operations, stockholders’ deficit and cash flows for the years then ended. These consolidated financial statements
are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial
statements based on our audits.



We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
our audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that we
considered appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.



In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the financial position of Cavitation Technologies, Inc.
as of June 30, 2016 and 2015, and the results of their operations and their cash flows for the years then ended, in conformity
with accounting principles generally accepted in the United States of America.



The accompanying consolidated financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2, the Company has
experienced recurring net losses since inception and has a stockholders deficit as of June 30, 2016. These matters raise substantial
doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are
also described in Note 2 to the financial statements. These financial statements do not include any adjustments that might result
from the outcome of this uncertainty.



/s/ Weinberg & Company, P.A.



Weinberg & Company, P.A.

Los Angeles, California

October 13, 2016



10







CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS



|                                                                                                                                                                      |  | June 30, |             |   | June 30, |  
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | -------- | ----------- | - | -------- | -
|                                                                                                                                                                      |  | 2016     |             |   | 2015     |  
|                                                                                                                                                                      |  |          |             |   |          |  
|ASSETS                                                                                                                                                                |  |          |             |   |          |  
|                                                                                                                                                                      |  |          |             |   |          |  
|Current assets:                                                                                                                                                       |  |          |             |   |          |  
|Cash and cash equivalents                                                                                                                                             |  | $        | 657,396     |   |          | $
|Inventory, net                                                                                                                                                        |  |          | 153,811     |   |          |  
|Total current assets                                                                                                                                                  |  |          | 811,207     |   |          |  
|                                                                                                                                                                      |  |          |             |   |          |  
|Property and equipment, net                                                                                                                                           |  |          | 122,641     |   |          |  
|Patents, net                                                                                                                                                          |  |          | 16,336      |   |          |  
|Other assets                                                                                                                                                          |  |          | 9,500       |   |          |  
|Total assets                                                                                                                                                          |  | $        | 959,684     |   |          | $
|                                                                                                                                                                      |  |          |             |   |          |  
|LIABILITIES AND STOCKHOLDERS’ DEFICIT                                                                                                                                 |  |          |             |   |          |  
|                                                                                                                                                                      |  |          |             |   |          |  
|Current liabilities:                                                                                                                                                  |  |          |             |   |          |  
|Accounts payable and accrued expenses                                                                                                                                 |  | $        | 171,029     |   |          | $
|Accrued payroll and payroll taxes due to officers                                                                                                                     |  |          | 994,033     |   |          |  
|Related party payable                                                                                                                                                 |  |          | 1,147       |   |          |  
|Advances from distributor, net                                                                                                                                        |  |          | 436,250     |   |          |  
|Total current liabilities                                                                                                                                             |  |          | 1,602,459   |   |          |  
|                                                                                                                                                                      |  |          |             |   |          |  
|Commitments and contingencies                                                                                                                                         |  |          |             |   |          |  
|                                                                                                                                                                      |  |          |             |   |          |  
|Stockholders’ deficit:                                                                                                                                                |  |          |             |   |          |  
|Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2016 and June 30, 2015, respectively                 |  |          | -           |   |          |  
|Common stock, $0.001 par value, 1,000,000,000 shares authorized, 193,997,906 and 184,968,551 shares issued and outstanding as of June 30, 2016 and 2015, respectively |  |          | 193,998     |   |          |  
|Additional paid-in capital                                                                                                                                            |  |          | 22,062,888  |   |          |  
|Common stock issuable, 9,029,251 shares                                                                                                                               |  |          | -           |   |          |  
|Accumulated deficit                                                                                                                                                   |  |          | (22,899,661 | ) |          |  
|Total stockholders’ deficit                                                                                                                                           |  |          | (642,775    | ) |          |  
|Total liabilities and stockholders’ deficit                                                                                                                           |  | $        | 959,684     |   |          | $



See accompanying notes, which are an integral
part of these consolidated financial statements



11







CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS



|                                     |  | For the Years Ended |            
|------------------------------------ |  | ------------------- | -----------
|                                     |  | June 30,            |            
|                                     |  | 2016                |            
|                                     |  |                     |            
|Revenue                              |  | $                   | 1,798,217  
|Cost of revenue                      |  |                     | 121,505    
|Gross profit                         |  |                     | 1,676,712  
|                                     |  |                     |            
|General and administrative expenses  |  |                     | 1,214,561  
|Research and development expenses    |  |                     | 29,371     
|Total operating expenses             |  |                     | 1,243,932  
|                                     |  |                     |            
|Net Income (loss)                    |  | $                   | 432,780    
|                                     |  |                     |            
|Net income (loss) per share,         |  |                     |            
|Basic and Diluted                    |  | $                   | 0.00       
|                                     |  |                     |            
|Weighted average shares outstanding, |  |                     |            
|Basic                                |  |                     | 193,997,906
|                                     |  |                     |            
|Diluted                              |  |                     | 194,352,745



See accompanying notes, which are an integral
part of these consolidated financial statements



12







CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT



|                                                         |  | Series A Preferred |   |  | Common Stock |   |   | Additional
     Paid- |  |  | Common 
    Stock |  |  | Accumulated |         |  |          |  
|-------------------------------------------------------- |  | ------------------ | - |  | ------------ | - | - | --------------------- |  |  | ----------------- |  |  | ----------- | ------- |  | -------- | -
|                                                         |  | Shares             |   |  | Amount       |   |   | Shares                |  |  | Amount            |  |  | in Capital  |         |  | Issuable |  
|Balance at June 30, 2014                                 |  |                    | - |  |              | $ | - |                       |  |  | 177,906,365       |  |  | $           | 177,906 |  |          | $
|                                                         |  |                    |   |  |              |   |   |                       |  |  |                   |  |  |             |         |  |          |  
|Fair value of shares of common stock issued for services |  |                    |   |  |              |   |   |                       |  |  | 1,068,000         |  |  |             | 1,068   |  |          |  
|Common stock issued for cash                             |  |                    |   |  |              |   |   |                       |  |  | 5,193,328         |  |  |             | 5,193   |  |          |  
|Common stock issued for cancelled options                |  |                    |   |  |              |   |   |                       |  |  | 800,858           |  |  |             | 801     |  |          |  
|Fair value of vested warrants                            |  |                    |   |  |              |   |   |                       |  |  |                   |  |  |             |         |  |          |  
|Net Loss                                                 |  |                    |   |  |              |   |   |                       |  |  |                   |  |  |             |         |  |          |  
|Balance at June 30, 2015                                 |  |                    | - |  |              |   | - |                       |  |  | 184,968,551       |  |  |             | 184,968 |  |          |  
|                                                         |  |                    |   |  |              |   |   |                       |  |  |                   |  |  |             |         |  |          |  
|Issuance of common stock                                 |  |                    |   |  |              |   |   |                       |  |  | 9,029,355         |  |  |             | 9,030   |  |          |  
|Net Income                                               |  |                    |   |  |              |   |   |                       |  |  |                   |  |  |             |         |  |          |  
|Balance at June 30, 2016                                 |  |                    | - |  |              | $ | - |                       |  |  | 193,997,906       |  |  | $           | 193,998 |  |          | $



See accompanying notes, which are an integral
part of these consolidated financial statements



13







CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS



|                                                                                     |  | Years Ended June 30, |           
|------------------------------------------------------------------------------------ |  | -------------------- | ----------
|                                                                                     |  | 2016                 |           
|                                                                                     |  |                      |           
|Operating activities:                                                                |  |                      |           
|Net income (loss)                                                                    |  | $                    | 432,780   
|Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |                      |           
|Depreciation and amortization                                                        |  |                      | 60,126    
|Fair value of common stock issued for services                                       |  |                      | -         
|Fair value of vested warrants                                                        |  |                      | -         
|Allowance for inventory obsolescence                                                 |  |                      | 18,792    
|Fair value of common stock issued for cancelled options                              |  |                      | -         
|                                                                                     |  |                      |           
|Effect of changes in:                                                                |  |                      |           
|Inventory                                                                            |  |                      | (37,004   
|Accounts payable and accrued expenses                                                |  |                      | (27,657   
|Accrued payroll and payroll taxes due to officers                                    |  |                      | (22,190   
|Advances from distributor                                                            |  |                      | 436,250   
|Reduction in advances due to realization of revenues from distributor                |  |                      | (1,620,701
|Net cash used in operating activities                                                |  |                      | (759,604  
|                                                                                     |  |                      |           
|Investing activities:                                                                |  |                      |           
|Purchase of property and equipment                                                   |  |                      | (61,565   
|Net cash used in investing activities                                                |  |                      | (61,565   
|                                                                                     |  |                      |           
|Financing activities:                                                                |  |                      |           
|Proceeds from sale of common stock                                                   |  |                      | -         
|Net cash provided by financing activities                                            |  |                      | -         
|                                                                                     |  |                      |           
|Net change in cash                                                                   |  |                      | (821,169  
|Cash, beginning of period                                                            |  |                      | 1,478,565 
|Cash, end of period                                                                  |  | $                    | 657,396   
|                                                                                     |  |                      |           
|Supplemental disclosures of cash flow information:                                   |  |                      |           
|Cash paid for interest                                                               |  | $                    | -         
|Cash paid for income taxes                                                           |  | $                    | -         



See accompanying notes, which are an integral
part of these consolidated financial statements



14







CAVITATION TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED JUNE 30, 2016 AND 2015



Note 1 - Organization



Cavitation Technologies, Inc. (referred
to herein, unless otherwise indicated, as “the Company,” “CTi,” “we,” “us,” and
“our”) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented,
and commercialized proprietary technology that may be used in liquid processing applications. CTi’s patented Nano Reactor®
is the critical component of CTi Nano Neutralization® System which has commercially been shown to reduce operating costs
and increase yields in refining vegetable oils. We have three US and one international patented systems, as well as eight US approved
patents for various processes, and have filed another fifteen US and international patents to employ our proprietary technology
in applications including vegetable and oil refining, waste water treatment, algae oil extraction, and alcoholic beverage enhancement.



In addition, we have commercialized our
CTi Nano Neutralization® System in the refining process of certain vegetable oils which has proven to reduce costs and
increase yields for our customers.



Note 2 - Basis of Presentation and Going Concern



Going Concern



The accompanying consolidated financial
statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the
Company as a going concern.  During the year ended June 30, 2016, the Company utilized $759,604 of cash in operations.
As of June 30, 2016, the Company had a working capital deficiency of $791,252 and a stockholders’ deficit of $642,775. The
Company has also been dependent on certain aspects of its funding from a technology agreement with a distributor. These factors,
among others, raise substantial doubt about the Company’s ability to continue as a going concern.



The accompanying consolidated financial
statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets
or the amounts and classification of liabilities that may result from an inability of the Company to continue as a going concern.
Management’s plan is to generate income from operations by continuing to license its technology globally through our strategic
partner with the Desmet Ballestra Group (Desmet). Pursuant to a R&D, Marketing and Technology License agreement with Desmet
that was signed in January 2016, Desmet has provided the Company with monthly advances of $50,000 which started in January of 2016
and will continue through August 2018 but can be terminated on each August 1 under certain circumstances. These advances are expected
to be applied against future sales to Desmet. During the year ended June 30, 2016 advances received from Desmet amounted to $500,000.



The Company will also attempt to raise
additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that
such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that
the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations.
Should management fail to obtain such financing, the Company may curtail its operations.



Note 3 - Significant Accounting Policies



Principles of Consolidation



The consolidated financial statements include
the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Intercompany transactions
and balances have been eliminated in consolidation.



Fair Value Measurement



FASB Accounting Standards Codification
(“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized
and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of
a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.



In addition to defining fair value, the
standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The
hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable
in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input
that is significant to the fair value measurement in its entirety. These levels are:



15







Level 1 - inputs are based upon unadjusted
quoted prices for identical instruments traded in active markets.



Level 2 - inputs are based upon significant
observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets
that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or
can be corroborated by observable market data for substantially the full term of the assets or liabilities.



Level 3 - inputs are generally unobservable
and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability.
The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow
models, and similar techniques.



As of June 30, 2016, the carrying value
of certain accounts such as inventory, accounts payable, accrued expenses and accrued payroll approximates their fair value due
to the short-term nature of such instruments.



Use of Estimates



The preparation of the consolidated financial
statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement
date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserves for
inventory obsolescence, valuing our stock options, stock warrants and common stock issued for services, among other items. Actual
results could differ from these estimates.



Revenue Recognition



Revenue from the sale of the Company’s
Nano Reactor® Systems is recognized when persuasive evidence of an agreement exists; shipment has occurred, including
transfer of title and risk of loss for product sales, or services have been rendered for service revenues; the price to the buyer
is fixed or determinable; and collectability is reasonably assured.



The Company is also entitled to certain
non-refundable profit share from its distributor from the sale of the reactors. Pursuant to the May 2012 agreement with its distributor,
the profit share was fixed and determinable at the time of shipment, and as such, recorded upon shipment and acceptance of the
reactors by the distributor. Pursuant to the January 2016 agreement with the Company’s distributor, the profit share is not
fixed at the time of delivery, and as such, revenue will be recognized when the profit share is fixed and determinable, which will
generally be upon delivery of the NANO Neutralization System by the distributor to its customer.



Cash



The Company considers highly liquid investments
with original maturities of three months or less to be cash equivalents. Cash equivalents are carried at cost which approximates
market value.



The Company maintains its cash with one
domestic financial institution. From time to time, cash balance in this domestic bank may exceed federally insured limits provided
by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000. As of June 30, 2016 and 2015, before adjustments
for outstanding checks and deposits in transit, the Company had approximately $657,000 and $1,489,000, respectively, on deposit
with one bank. The Company believes that no significant concentration of credit risk exists with respect to this cash balances
because of its assessment of the creditworthiness and financial viability of this financial institution.



Accounts Receivable



The Company evaluates the collectability
of our trade accounts receivable based on a number of factors. In circumstances where it becomes aware of a specific customer’s
inability to meet its financial obligations to us, a specific reserve for bad debts is estimated and recorded which reduces the
recognized receivable to the estimated amount that management believes will ultimately be collected. In addition to specific customer
identification of potential bad debts, bad debt charges are recorded based on our historical losses and an overall assessment of
past due trade accounts receivable outstanding.



Inventory



Inventory, net of an allowance for excess
quantities and obsolescence, is stated at the lower of cost or market. Cost is determined on a specific item basis. Inventory is
composed of finished goods and represents costs incurred to manufacture the Company’s Nano Reactor® systems.



16







Property and Equipment



Property and equipment is presented at
cost less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of
the assets. Betterments, renewals, and extraordinary repairs that extend the life of the assets are capitalized; other repairs
and maintenance charges are expensed as incurred. The cost and related accumulated depreciation applicable to retired assets are
removed from the Company’s accounts, and the gain or loss on dispositions, if any, is recognized in the consolidated statements
of operations.



Property and equipment are recorded at
cost and depreciated using the straight-line method over the following estimated useful lives.



|Leasehold improvements    |  | Shorter of life of asset or lease
|------------------------- |  | ---------------------------------
|Furniture                 |  | 5-7 Years                        
|Office equipment          |  | 5 Years                          
|Lab equipment             |  | 4 Years                          
|Skid systems (demo units) |  | 4 Years                          



Management assesses the carrying value
of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the
asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized
to write down the asset to its estimated fair value. For the years ended June 30, 2016 and 2015, the Company did not recognize
any impairment for its property and equipment.



Patents



Capitalized patent costs represent legal
fees associated with procuring and filing patent applications. The Company accounts for patents in accordance with ASC 350-30,
General Intangibles Other Than Goodwill . The Company has five patents issued in fiscal 2013, 2012 and 2011. As of June
30, 2016, the Company has a total of 25 patents pending. The patents have duration of twenty years from filing date. The Company
amortizes its patents over a four-year period which we believe is a reasonable estimate based upon its estimate of time until the
next generation of reactors is developed or until other forms of competition appear.



During the year ended June 30, 2016, the
Company recognized patent amortization expense of $20,830. As of June 30, 2016, total capitalized patent costs amounted to $129,363
and accumulated amortization of $113,027 or a net balance of $16,336.



During the year ended June 30, 2015, the
Company recognized patent amortization expense of $30,307. As of June 30, 2015, total capitalized patent costs amounted to $129,363
and accumulated amortization of $92,127 or a net balance of $37,166.



At June 30, 2016, future estimated patent
amortization costs are as follows:



|Year Ended |  |        |       
|---------- |  | ------ | ------
|June 30,   |  | Amount |       
|           |  |        |       
|2017       |  |        | 13,501
|2018       |  |        | 2,835 
|Total      |  | $      | 16,336



Impairment of Intangible and Long-Lived
Assets



In accordance with ASC 350-30, General
Intangibles Other than Goodwill , the Company evaluates amortizable intangibles and long-lived assets for impairment whenever
events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances
exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over
their estimated useful lives against their respective carrying amount. Impairment, if any, is based on the excess of the carrying
amount over the fair value, based on market value when available, or discounted expected cash flows, of those assets and is recorded
in the period in which the determination is made. Based on the Company annual impairment tests, management believes there is no
impairment of its intangibles and long-lived assets as of June 30, 2016 and 2015. There can be no assurance, however, that market
conditions will not change or demand for the Company’s products under development will continue. Either of these could result
in future impairment of intangibles and long-lived assets.



17







Share-Based Compensation



The Company periodically issues stock options
and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company
accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the
Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting
period. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative
guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement
date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary
performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over
the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the
non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the
measurement date.



The fair value of the Company’s common
stock option and warrant grants is estimated using the Black-Scholes option pricing model, which uses certain assumptions related
to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation
expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The
assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.



Income Taxes



The Company accounts for income taxes in
accordance with ASC 740-10, Income Taxes .  The Company recognizes deferred tax assets and liabilities to reflect
the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable
to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred
tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred
tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.



ASC 740-10 prescribes a recognition threshold
that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition,
measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. The Company
classifies interest and penalties as a component of interest and other expenses. To date, there have been no interest or penalties
assessed or paid.



The Company measures and records uncertain
tax positions by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected
to be taken in a tax return.  Only tax positions meeting the more-likely-than-not recognition threshold at the effective
date may be recognized or continue to be recognized.



Advertising Costs



Advertising costs (including marketing
expense) incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $45,241 and $23,285
for the years ended June 30, 2016 and 2015 respectively and was reported as part of General and administrative expenses in the
accompanying Consolidated Statements of Operations.



Research and Development Costs



Research and development expenses relate
primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are
expensed as incurred. Total research and development costs recorded during the years ended June 30, 2016 and 2015 amounted to $29,371
and $22,310, respectively.



Warranty Policy



The Company provides a limited warranty
with every set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty
policy, and management determined no accrual for warranty reserve was necessary at June 30, 2016 and 2015.



18







Net Income (Loss) Per Share



The Company’s computation of earnings
per share (“EPS”) includes basic and diluted EPS.  Basic EPS is measured as the income available to common stockholders
divided by the weighted average common shares outstanding for the period.  Diluted income per share reflects the potential
dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised
or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if
they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per
share, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase
common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury
stock method only when the average market price of the common stock during the period exceeds the exercise price of the options
and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease
loss per share) are excluded from the calculation of diluted EPS.



The following table sets forth the computation
of basic and diluted income (loss) per common share.



|                                             |  | June 30, |            
|-------------------------------------------- |  | -------- | -----------
|                                             |  | 2016     |            
|                                             |  |          |            
|Net income (loss)                            |  | $        | 432,780    
|                                             |  |          |            
|Weighted average common shares – basic       |  |          | 193,997,906
|Dilutive effect of outstanding stock options |  |          | 354,839    
|Weighted average shares – diluted            |  |          | 194,352,745
|                                             |  |          |            
|Net income (loss) per common share:          |  |          |            
|Basic and Diluted                            |  | $        | 0.00       



There were no adjustments to net income
(loss) required for purposes of computing diluted earnings per share. At June 30, 2016 and 2015, the Company excluded the outstanding
securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted
earnings per share, as their effect would have been antidilutive.



|         |  | June 30, 2016 |            |  | June 30, 2015 | 
|-------- |  | ------------- | ---------- |  | ------------- | 
|Options  |  |               | 12,241,153 |  |               | 
|Warrants |  |               | 64,326,510 |  |               | 



Recent Accounting Pronouncements



In May 2014, the Financial Accounting Standards
Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers . ASU 2014-09 is
a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current
U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies
recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require
additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts,
including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.
ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in
annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition
to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process
of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures.



In August 2014, the FASB issued Accounting
Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern
, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. ASU
2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern
within one year of the date the financial statements are issued.  An entity must provide certain disclosures if conditions
or events raise substantial doubt about the entity’s ability to continue as a going concern.  ASU 2014-15 is effective
for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is
currently evaluating the impact the adoption of ASU 2014-15 on the Company’s financial statements and disclosures.



19







In February 2016, the FASB issued Accounting
Standards Update No. 2016-02, Leases . ASU 2016-02 requires a lessee to record a right of use asset and a corresponding
lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim
and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition
approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest
comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process
of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures.



Other recent accounting pronouncements
issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities
and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future
consolidated financial statements.



Dependence on Desmet Ballestra



The Company’s revenue is entirely
dependent on Desmet Ballestra who is its exclusive distribution agent with regard to the CTi Nano Neutralization® System
for edible oils. During the year ended June 30, 2016 and 2015, 100% of the Company’s revenue was derived from Desmet (see
Note 4).



Note 4 - Agreement with Desmet Ballestra



2012 Agreement



On May 14, 2012 the Company signed a three-year
global Research and Development, Marketing and Technology License Agreement with the n.v. Desmet Ballestra Group s.a. (Desmet),
a Belgian company that is actively marketing the NANO Neutralization System , the key component of which is the Company’s
reactor to soybean and other vegetable oil refiners. The agreement provided Desmet (licensee) a limited, exclusive license and
right to develop, design and supply Nano Reactor® systems which incorporate Nano Reactor® devices on a global basis but
is limited to oils and fats and oleo chemical applications. The Company (licensor) remains owner of the current patents and patent
applications but Desmet will be co-owner of any new process patent applications jointly developed. Desmet provided, under certain
conditions, limited monthly advance payments of $125,000 against future sales to CTi through May 15, 2015. The agreement with Desmet
expired in May 2015.



Pursuant to the 2012 Agreement, the Company
was recognizing revenue from the sale of the reactors upon shipment and acceptance by Desmet as the Company had no further obligations
to Desmet other than the reactor’s two-year standard warranty. In addition, the Company was also entitled to a non-refundable
share in gross margin or profit from the sale of Desmet’s integrated neutralization system to its customer of which the reactors
are an integral component. Such revenues were recognized upon shipment of the reactors to Desmet as these amounts were fixed and
the Company had no further obligation or commitment in the installation of the integrated neutralization system to Desmet’s
customer, other than the reactors warranty.



During the years ended June 30, 2016 and
2015, the Company recorded revenues of $1,620,701 and $489,255 pursuant to the 2012 agreement and as of June 30, 2015, $1,620,701
of advance payments were received.



As of June 30, 2016, the Company had no
further obligations to Desmet under this agreement.



2016 Agreement



On January 22, 2016, the Company signed
a similar three-year agreement with Desmet effective August 1, 2015. As part of the agreement, Desmet will provide, under certain
conditions, limited monthly advance payments of $50,000 against future sales to CTi. The agreement may be terminated by Desmet
every August 1 should Desmet and its affiliates fail to convert a minimum of six Nano Reactors systems to sold status during the
period of June 1 to May 31. The agreement may also be terminated in case the Company were to lose its rights under the patents
and patent applications being used in the Company’s CTi NANO Neutralization System.



Pursuant to the 2016 Agreement, the Company
recognizes revenue from sale of reactors upon shipment and acceptance by Desmet, as the Company has no further obligations to Desmet
other than the reactor’s two-year standard warranty. In addition, Desmet now pays for such reactors on credit terms and the
amount of the sale is recorded as a receivable upon acceptance by Desmet. The Company also continues to receive a share in gross
margin or profit from the sale of Desmet’s integrated neutralization system to its customer of which the reactors are an
integral component, however, such amount is now subject to adjustment based on certain factors including costs over run. The Company
deemed that such amount is not yet fixed and determinable upon shipment of the reactors. As a result, the corresponding revenue
is now being recognized upon installation and acceptance of the integrated neutralization system by Desmet’s customer.



20







During the year ended June 30, 2016, the
Company recorded revenues of $177,516 and received $500,000 of advance payments pursuant to the 2016 agreement. As of June 30,
2016, $63,750 of the recorded revenues was not yet collected, as such, for financial reporting purposes, the Company deducted this
amount from the advance payments received which resulted in a net balance of $436,250 in advances from distributor, net as of that
date.



Note 5 - Property and Equipment



Property and equipment consists of the
following as of June 30, 2016 and June 30, 2015:



|                                                |  | June 30, |          |   | June 30, |  
|----------------------------------------------- |  | -------- | -------- | - | -------- | -
|                                                |  | 2016     |          |   | 2015     |  
|                                                |  |          |          |   |          |  
|Leasehold  improvement                          |  | $        | 2,475    |   |          | $
|Furniture                                       |  |          | 26,837   |   |          |  
|Office equipment                                |  |          | 1,499    |   |          |  
|Equipment                                       |  |          | 68,380   |   |          |  
|Systems                                         |  |          | 352,655  |   |          |  
|                                                |  |          | 451,846  |   |          |  
|Less: accumulated depreciation and amortization |  |          | (329,205 | ) |          |  
|Property & Equipment, net                       |  | $        | 122,641  |   |          | $



Depreciation expense for the years ended
June 30, 2016 and 2015 amounted to $39,296 and $59,473, respectively and was reported as part of General and administrative expenses
in the accompanying Consolidated Statements of Operations.



Note 6 - Accrued Payroll and Payroll Taxes to Officers and
former officers



As of June 30, 2016 and 2015, the Company
had accrued unpaid salaries to officers and former officers amounting to $994,033 and $1,016,223, respectively.



Note 7 - Stockholders’ Deficit



Common Stock



Year ended June 30, 2016



On September 25, 2015, the Company issued
9,029,255 shares of common stock pursuant to a settlement of notes payable in April 2014. These shares were reflected as Common
Stock issuable in the accompanying Statement of Changes in Stockholders’ Deficit as of June 30, 2015, such amounts were reclassified
to additional paid in capital upon their issuance during the year ended June 30, 2016.



Year ended June 30, 2015



In October 2014, the Company issued 1,068,000
shares of common stock valued at $64,080 as payment to a service provider. These shares were valued at fair value at the date of
issuance.



In July 2014 the Company issued 5,193,328
shares of common stock to various entities and individuals in exchange for cash proceeds of $375,498, net of commissions of $14,359.
In addition, the Company also granted these entities and individuals five year, fully vested warrants to purchase 5,193,328 shares
of common stock at $0.12 per share. The shares were issued in reliance on Section 4(2) of the Securities Act of 1933, as amended.
The shares were not offered via general solicitation to the public.



21







In June 2015, we issued an aggregate of
800,858 shares of common stock to a consultant in exchange for the cancellation of 800,858 fully vested stock options that were
granted in December 2012. As a result, the Company recognized compensation cost of $442 to account for the incremental difference
in fair value of the 800,858 shares of common stock and the fair value of the cancelled 800,858 stock options.



Preferred Stock



On March 17, 2009, the Company filed
an Amended and Restated Articles of Incorporation and created two  new series of preferred stock, the first of which
is designated Series A Preferred Stock and the second of which is designated as Series B Preferred Stock. The total number
of shares of Common Stock which this corporation has authority to issue is 1,000,000,000 shares of Common Stock and 10,000,000
shares of Preferred Stock of which 5,000,000 shares are designated as Series A Preferred Stock, and 5,000,000 shares are designated
as Series B Preferred Stock, with the rights, preferences and privileges of the Series B Preferred Stock to be designated by the
Board of Directors. Each share of Common Stock and Preferred Stock has a par value of $0.001. As of June 30, 2016 and 2015, there
are no shares of Series A or Series B Preferred Stock issued and outstanding.



Stock Options



The Company has not adopted a formal stock
option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly-owned subsidiary, Hydrodynamic
Technology, Inc. In addition, the Company has made periodic non- plan grants. A summary of the stock option activity from June
30, 2016 and 2015 is as follows:



|                             |  |         |            |   |           |   |      | Weighted-   | 
|---------------------------- |  | ------- | ---------- | - | --------- | - | ---- | ----------- | 
|                             |  |         |            |   |           |   |      | Average     | 
|                             |  |         |            |   | Weighted- |   |      | Remaining   | 
|                             |  |         |            |   | Average   |   |      | Contractual | 
|                             |  |         |            |   | Exercise  |   |      | Life        | 
|                             |  | Options |            |   | Price     |   |      | (Years)     | 
|                             |  |         |            |   |           |   |      |             | 
|Outstanding June 30, 2014    |  |         | 13,611,815 |   |           | $ | 0.44 |             | 
|                             |  |         |            |   |           |   |      |             | 
|- Granted                    |  |         | -          |   |           |   | -    |             | 
|- Forfeited/Replaced         |  |         | (800,858   | ) |           |   | -    |             | 
|- Exercised                  |  |         | -          |   |           |   | -    |             | 
|- Expired                    |  |         | -          |   |           |   | -    |             | 
|Outstanding at June 30, 2015 |  |         | 12,810,957 |   |           | $ | 0.44 |             | 
|- Granted                    |  |         | -          |   |           |   | -    |             | 
|- Forfeited/Replaced         |  |         | -          |   |           |   | -    |             | 
|- Exercised                  |  |         | -          |   |           |   | -    |             | 
|- Expired                    |  |         | (214,965   | ) |           |   | -    |             | 
|Outstanding at June 30, 2016 |  |         | 12,595,992 |   |           | $ | 0.44 |             | 



In June 2015, the Company cancelled fully
vested stock options to purchase 800,858 shares of common stock that were granted to a consultant in prior periods. In exchange
for the cancellation, the Company issued to the consultant 800,858 shares of common stock.



As of June 30, 2016 and 2015, all outstanding
options were fully vested and exercisable. The intrinsic value of the outstanding options as of June 30, 2016 was $0. The following
table summarizes additional information concerning options outstanding and exercisable at June 30, 2016.



22







|         |      |  | Options Outstanding |  |            | Options Exercisable | 
|-------- | ---- |  | ------------------- |  | ---------- | ------------------- | 
|         |      |  |                     |  |            | Weighted            | 
|         |      |  |                     |  |            | Average             | 
|Exercise |      |  | Number              |  |            | Remaining           | 
|Price    |      |  | of Shares           |  |            | Life (Years)        | 
|         |      |  |                     |  |            |                     | 
|         | 0.03 |  |                     |  | 11,174,021 |                     | 
|         | 0.33 |  |                     |  | 350,677    |                     | 
|         | 0.67 |  |                     |  | 1,071,294  |                     | 
|         |      |  |                     |  | 12,595,992 |                     | 



Warrants



A summary of the Company’s warrant activity and related
information from as of June 30, 2016 and 2015 is as follows.



|                             |  |          |            |   |           |   |      | Weighted-   | 
|---------------------------- |  | -------- | ---------- | - | --------- | - | ---- | ----------- | 
|                             |  |          |            |   |           |   |      | Average     | 
|                             |  |          |            |   | Weighted- |   |      | Remaining   | 
|                             |  |          |            |   | Average   |   |      | Contractual | 
|                             |  |          |            |   | Exercise  |   |      | Life        | 
|                             |  | Warrants |            |   | Price     |   |      | (Years)     | 
|                             |  |          |            |   |           |   |      |             | 
|Outstanding at June 30, 2014 |  |          | 63,066,514 |   |           | $ | 0.06 |             | 
|                             |  |          |            |   |           |   |      |             | 
|Granted                      |  |          | 5,193,329  |   |           | $ | 0.12 |             | 
|Exercised                    |  |          | -          |   |           |   |      |             | 
|Expired                      |  |          | -          |   |           |   |      |             | 
|Outstanding at June 30, 2015 |  |          | 68,259,843 |   |           | $ | 0.07 |             | 
|                             |  |          |            |   |           |   |      |             | 
|Granted                      |  |          | -          |   |           |   | -    |             | 
|Exercised                    |  |          | -          |   |           |   | -    |             | 
|Expired                      |  |          | (3,933,333 | ) |           |   |      |             | 
|Outstanding at June 30, 2016 |  |          | 64,326,510 |   |           | $ | 0.07 |             | 



In July 2014, the Company issued warrants
to purchase 5,193,329 shares of common stock to the purchasers of our common stock offering. The warrants are exercisable at $0.12
per share, vesting immediately and expiring in 5 years from the grant date.



During the year ended June 30, 2015, the
Company recognized compensation expense of $245,375 to account for the fair value of vested warrants granted to a consultant and
a member of our Board of Directors.



As of June 30, 2016 and 2015, all outstanding
warrants were fully vested and exercisable. The intrinsic value of the outstanding warrants as of June 30, 2016 and 2015 was $0
and $651,999, respectively. The following table summarizes additional information concerning warrants outstanding and exercisable
at June 30, 2016.



23







|         |             |  | Warrants Outstanding |  |            | Warrants Exercisable | 
|-------- | ----------- |  | -------------------- |  | ---------- | -------------------- | 
|         |             |  |                      |  |            | Weighted             | 
|         |             |  |                      |  |            | Average              | 
|Exercise |             |  | Number               |  |            | Remaining            | 
|Price    |             |  | of Shares            |  |            | Life (Years)         | 
|         |             |  |                      |  |            |                      | 
|         | 0.04 - 0.07 |  |                      |  | 43,999,851 |                      | 
|         | 0.12        |  |                      |  | 20,326,659 |                      | 
|         |             |  |                      |  | 64,326,510 |                      | 



The table below represents the assumptions
used in valuing the stock options and warrants granted in fiscal 2016 and 2015:



|                        |  | Year Ended June 30, |  
|----------------------- |  | ------------------- | -
|                        |  | 2016                |  
|                        |  |                     |  
|Expected life in years  |  |                     | -
|Stock price volatility  |  |                     | -
|Risk free interest rate |  |                     | -
|Expected dividends      |  |                     | -
|Forfeiture rate         |  |                     | -



The assumptions used in the Black Scholes
models referred to above are based upon the following data: (1) the contractual life of the underlying non-employee options
is the expected life. The expected life of the employee option is estimated by considering the contractual term of the option,
the vesting period of the option, the employees’ expected exercise behavior and the post-vesting employee turnover rate.
(2) The expected stock price volatility was based upon the Company’s historical stock price over the expected term of
the option. (3) The risk free interest rate is based on published U.S. Treasury Department interest rates for the expected terms
of the underlying options. (4) The expected dividend yield was based on the fact that the Company has not paid dividends to common
shareholders in the past and does not expect to pay dividends to common shareholders in the future. (5) The expected forfeiture
rate is based on historical forfeiture activity and assumptions regarding future forfeitures based on the composition of current
grantees.



Note 10 - Income Taxes



Total income tax expense differed from
the amounts computed by applying the U.S. Federal income tax rate of 34% to income before income tax expense as a result of the
NOL carry forward. Therefore, the Company’s effective tax rate is 0.0%. The Company files income tax returns in the United
States (“Federal”) and California (“State”) jurisdictions. The Company is subject to Federal and State
income tax examinations by tax authorities for all years since its inception.



At June 30, 2016, the Company had Federal
and State net operating loss carry forwards available to offset future taxable income of approximately $8.7 million. These carry
forwards will begin to expire in the year ending June 30, 2017 through 2023, subject to IRS limitations, including change in ownership.



The Company periodically evaluates the
likelihood of the realization of deferred tax assets, and adjusts the carrying amount of the deferred tax assets by a valuation
allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company
considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative
earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available
to us for tax reporting purposes, and other relevant factors.



At June 30, 2016, based on the weight of
available evidence, including cumulative losses in recent years and expectations of future taxable income, the Company determined
that it was more likely than not that its deferred tax assets of approximately $4.4 million would not be realized. Accordingly,
the Company has recorded a valuation allowance for 100% of its cumulative deferred tax assets. The components of our deferred tax
assets are as follows.



24







|                                 |  | June 30, |           
|-------------------------------- |  | -------- | ----------
|                                 |  | 2016     |           
|Net Operating loss carryforwards |  | $        | 3,585,000 
|Stock compensation expense       |  |          | 725,000   
|Amortization of Patents          |  |          | 58,000    
|Reserve for Obsolete Inventory   |  |          | 68,000    
|Total net deferred tax assets    |  |          | 4,436,000 
|Less valuation discount          |  |          | (4,436,000
|Net deferred tax assets          |  | $        | -         



A reconciliation of the difference between
the expense and income taxes as the statutory US federal income tax are as follows:



|                                                                 |  | June 30, |         
|---------------------------------------------------------------- |  | -------- | --------
|                                                                 |  | 2016     |         
|Computed tax provision (benefit) at federal statutory rate (34%) |  | $        | (254,000
|State income taxes (7%), net of federal benefit                  |  |          | (52,000 
|Valuation allowance                                              |  |          | 306,000 
|Income tax provision                                             |  | $        | -       



As a result of the implementation of certain
provisions of ASC 740-10, the Company performed an analysis of its previous tax filings and determined that there were no positions
taken that it considered uncertain. Therefore, there were no unrecognized tax benefits as of June 30, 2016.



Future changes in the unrecognized tax
benefit are not expected to have an impact on the effective tax rate due to the existence of the valuation allowance. The Company
estimates that the unrecognized tax benefit will not change within the next twelve months. The Company will continue to classify
income tax penalties and interest, if any, as part of interest and other expenses in its consolidated statements of operations.
There is no interest or penalties accrued as of June 30, 2016.



The following summarizes the open tax years
for each major jurisdiction:



|Jurisdiction |  | Open Tax Years
|------------ |  | --------------
|             |  |               
|Federal      |  | 2011 - 2015   
|California   |  | 2010 - 2015   



The Company’s net operating loss
carry forwards are subject to IRS examination until they are utilized and such tax years are closed.



25









Note 11 - Commitments and Contingencies



Lease Agreement



The Company leases approximately 5,000
square feet of office and warehouse space under a non-cancellable lease agreement through February 1, 2018.  Monthly payments
are approximately $5,000 per month. The Company has a security deposit of $9,500 associated with this lease. Future minimum lease
payments under our non-cancelable operating lease through February 2018 is as follows:



|Year End      |  | Amount |       
|------------- |  | ------ | ------
|June 30, 2017 |  | $      | 60,000
|June 30, 2018 |  |        | 35,000
|Total         |  | $      | 95,000



Total rent expense was $53,359 and $61,236
for the years ended June 30, 2016 and 2015 and was reported as part of General and administrative expenses in the accompanying
Consolidated Statements of Operations,



Royalty Agreements



On July 1, 2008, the Company’s wholly
owned subsidiary entered into Patent Assignment Agreements with two parties, its President as well as its former Chief Executive
Officer (CEO) and current Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation
processes invented by the President and former CEO/ current Technology Senior Manager have been assigned to the Company.  In
exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/ current Technology
Senior Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements
were subsequently assigned to Cavitation Technologies on May 13, 2010. The Company’s former CEO/ current Technology
Senior Manager and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any
gross revenue generated through June 30, 2016.



On April 30, 2008 (as amended November
22, 2010), the Company’s wholly owned subsidiary entered into an employment agreement with the Director of Chemical and Analytical
Department (the “Inventor”) providing that the Inventor shall receive an amount equal to 5% of actual gross royalties
received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor
was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent
year. As of June 30, 2016, no patents have been granted in which this person is the legally named inventor.



Litigation



The Company may
be involved in certain legal proceedings that arise from time to time in the ordinary course of its business. Except for income
tax contingencies (commencing April 1, 2009), the Company records accruals for contingencies to the extent that management concludes
that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with
the contingency are expensed as incurred.



| | a. | In August 2014, a former
employee and former Director filed an administrative Complaint for approximately $179,000 in unpaid wages, plus penalties and
interest, with the California Labor Commissioner’s Office (CLCO).  In January 2016, the CLCO ruled in favor of the
Company and dismissed the case. As a result of this ruling, the Company’s obligation to the former employee and former Director
only amounted to approximately $134,000 which was already accrued in prior periods and included as part of Accrued Payroll and
payroll taxes due to officers in the accompanying balance sheet.
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



In February
2016, the former employee and former Director appealed this ruling to the Los Angeles County Superior Court.  In addition
to defending itself, the Company also has filed a cross-complaint against the former employee and former Director for breach of
contract and breach of fiduciary duty as a Director.  Trial is currently scheduled to begin in 2017. Based upon available
information at this very early stage of litigation, Management believes the likelihood of material loss resulting from this lawsuit
to be remote.



| | b. | The Company has several patents issued by the US Patent Office with regards to the use and efficacy of its Nano Reactors. In August 2015, a competitor, Arisdyne System filed a complaint challenging the patentability of certain claims of the Company’s Patent No. 8,911,808 B2 or Patent 808. Patent 808 is currently being used in the reactors purchased by the Company’s distributor, Desmet. In January 2016, the Company and Arisdyne System terminated the complaint with no monetary compensation paid.
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



26







ITEM 9.  CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE



None.



ITEM 9A.  CONTROLS AND PROCEDURES



Disclosure Controls and Procedures



In accordance with rule 13a-15(a), our
management must maintain disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities and Exchange Act of
1934, or the Exchange Act, to provide reasonable assurance that information required to be disclosed by us in reports that we file
or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities
and Exchange Commission rules and forms, and accumulated and communicated to our management, including our principal executive
officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.



In accordance with Rule 13a-15(b) and (c),
management must also evaluate the effectiveness of these disclosure control and procedures at the end of each fiscal year. As of
June 30, 2016, we carried out an evaluation, under the supervision and with the participation of ours principal executive officer
and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based
upon that evaluation, our principal executive officer and principal financial officer concluded that these disclosure controls
and procedures were not effective as of June 30, 2016.



Report of Management on Internal Control
over Financial Reporting



Management is responsible for establishing
and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Our internal
control over financial reporting is designed under the supervision of our principal executive and principal financial officer,
and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles and includes those policies and procedures that:



(i) pertain to the maintenance of records
that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;



(ii) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts
and expenditures are being made only in accordance with authorizations of our management and directors; and



(iii) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect
on the financial statements.



Under the supervision and with the participation
of our management, including our Principal Executive Officer and Principal Financial Officer, we conducted an evaluation of the
effectiveness of our internal controls and procedures, (as defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the
Securities Exchange Act of 1934, as amended (Exchange Act)) as of the year ended June 30, 2016. Based on Management conducted as
assessment of our internal control over financial reporting based on the framework and criteria established by the Committee of
Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based
on this evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our internal controls over financial
reporting are ineffective. Our management discovered certain conditions that we deemed to be material weaknesses and significant
deficiencies in our internal controls, as follows:



A lack of accounting
and finance resources as well as effective oversight by those in charge of governance resulted in insufficient controls over timely
financial statement preparation and review as well as the preparation and review around accounting for certain complex transactions.



The design of monitoring
controls used to assess the design and operating effectiveness of our internal controls is inadequate. We also do not have an adequate
internal process to report deficiencies in internal control to management on a timely basis.



We are in the continuous process of improving
our internal control over financial reporting in an effort to eliminate these material weaknesses through improved supervision
and training of our staff, but additional effort is needed to fully remedy these deficiencies. We intend on hiring the necessary
staff to address the weaknesses once additional capital is obtained which will allow full operations to commence. Because of its
inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those
systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.



We have taken numerous steps to address
the underlying causes of the internal control deficiencies, primarily through the development and implementation of policies, improved
processes and documented procedures, the retention of third-party experts and contractors, and the hiring of additional accounting
personnel with technical accounting and inventory accounting experience.



27







Changes in Internal Control over Financial
Reporting



There have been no changes in our internal
control over financial reporting during the quarter ended June 30, 2016 that materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.



Attestation



Pursuant to Item 308(b) of Regulation S-K,
as amended by the Dodd-Frank Wall Street Reform and Consumer Protection Act (Wall Street Reform Act), this report does not include
an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting.
The Wall Street Reform Act permanently exempts small public companies from the requirement to obtain an external audit on the effectiveness
of internal financial reporting controls.



ITEM 9B.  Other Information



None.



28







PART III



ITEM 10. Directors, Executive Officers
and Corporate Governance.



Certain of the information required by
this item will be contained in the Form 10-K/A to be filed within 120 days of June 30, 2016. Such information is incorporated into
this item by reference.



ITEM 11. Executive Compensation.



Certain of the information required by
this item will be contained in the Form 10-K/A to be filed within 120 days of June 30, 2016. Such information is incorporated into
this item by reference.



ITEM 12. Security Ownership of Certain
Beneficial Owners and Management, and Related Stockholder Matters.



Certain of the information required by
this item will be contained in the Form 10-K/A to be filed within 120 days of June 30, 2016. Such information is incorporated into
this item by reference.



ITEM 13. Certain Relationships
and Related Transactions, and Director Independence.



Certain of the information required by
this item will be contained in the Form 10-K/A to be filed within 120 days of June 30, 2016. Such information is incorporated into
this item by reference.



ITEM 14. Principal Accountant Fees and
Services.



Certain of the information required by
this item will be contained in the Form 10-K/A to be filed within 120 days of June 30, 2016. Such information is incorporated into
this item by reference.



29







PART IV



ITEM 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES



(a) The following documents were filed
as part of the annual report on Form 10-K on October 13, 2016 and are incorporated by reference:



1.   Financial Statements



The financial statements were filed as
part of this report under Item 8 “Financial Statements and Supplementary Data” on October 13, 2016.



2.   Financial Statement Schedules



All other schedules are omitted because
they are not applicable or the required information is presented in the financial statements and notes thereto.



3.   Exhibits



The exhibits required by Item 601 of Regulation
S-K are included in Item 15(b) below.



(b) - Exhibits.



|               |  |                                                                                                                                                       |  |                |  | Incorporated by Reference
|-------------- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------- |  | -------------- |  | -------------------------
|Exhibit Number |  | Exhibit Description                                                                                                                                   |  | Filed Herewith |  | Form                     
|               |  |                                                                                                                                                       |  |                |  |                          
|3(i)(a)        |  | Articles of Incorporation - original name of Bioenergy, Inc.                                                                                          |  |                |  | SB-2                     
|3(i)(b)        |  | Articles of Incorporation - Amended and Restated                                                                                                      |  |                |  | 10-Q                     
|3(i)(c)        |  | Articles of Incorporation - Amended and Restated                                                                                                      |  |                |  | 10-Q                     
|3(i)(d)        |  | Articles of Incorporation - Amended; increase in authorized shares                                                                                    |  |                |  | 8-K                      
|3(i)(e)        |  | Articles of Incorporation - Certificate of Amendment; forward split                                                                                   |  |                |  | 10-Q                     
|10.1           |  | Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008.                                                                  |  |                |  | 8-K                      
|10.2           |  | Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008.                                                              |  |                |  | 8-K                      
|10.3           |  | Assignment of Patent Assignment Agreement between the Company and Roman Gordon                                                                        |  |                |  | 8-K                      
|10.4           |  | Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky                                                                    |  |                |  | 8-K                      
|10.5           |  | Employment Agreement between the Company and Roman Gordon date March 17, 2008                                                                         |  |                |  | 10-K/A                   
|10.6           |  | Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008                                                                    |  |                |  | 10-K/A                   
|10.7           |  | Employment Agreement with R.L. Hartshorn dated Sept. 22, 2009                                                                                         |  |                |  | 10-Q                     
|10.8           |  | Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008                        |  |                |  | 10-Q                     
|10.9           |  | Board of Director Agreement - James Fuller                                                                                                            |  |                |  | 10-Q                     
|10.10          |  | Technology and License Agreement with Desmet Ballestra dated 14 May 2012                                                                              |  |                |  | 10-K                     
|10.11          |  | Convertible Note Payable - Prolific Group LLC - $25,000                                                                                               |  |                |  | 10-Q                     
|10.12          |  | Convertible Note Payable - Tripod Group LLC - $30,000                                                                                                 |  |                |  | 10-Q                     
|14.1           |  | Code of Business Conduct and Ethics*                                                                                                                  |  |                |  | 10-K                     
|31.1           |  | Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002                                                      |  | X              |  |                          
|31.2           |  | Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002                                                      |  | X              |  |                          
|32.1           |  | Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |  | X              |  |                          
|32.2           |  | Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted                                                            |  | X              |  |                          
|               |  | pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                            |  |                |  |                          
|99.1           |  | Loan Agreement - Desmet Ballestra - Oct. 26, 2010                                                                                                     |  |                |  | 10-Q                     
|101.INS        |  | XBRL Instance Document                                                                                                                                |  |                |  | 10-K                     
|101.SCH        |  | XBRL Taxonomy Extension Schema                                                                                                                        |  |                |  | 10-K                     
|101.CAL        |  | XBRL Taxonomy Extension Calculation Linkbase                                                                                                          |  |                |  | 10-K                     
|101.DEF        |  | XBRL Taxonomy Extension Definition Linkbase                                                                                                           |  |                |  | 10-K                     
|101.LAB        |  | XBRL Taxonomy Extension Label Linkbase                                                                                                                |  |                |  | 10-K                     
|101.PRE        |  | XBRL Taxonomy Extension Presentation Linkbase                                                                                                         |  |                |  | 10-K                     



| | * | In accordance with Regulation
S-K 406 of the Securities Act of 1934, we undertake to provide to any person without charge, upon request, a copy of our “Code
of Business Conduct and Ethics”. A copy may be requested by sending an email to info@cavitationtechnologies.com.
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



(c) - Financial Statement Schedules



See Item (a) 2 above.



30







SIGNATURES



PURSUANT TO THE REQUIREMENTS OF THE SECURITIES
EXCHANGE ACT OF 1934, THIS REPORT HAS BEEN SIGNED BELOW BY THE FOLLOWING PERSONS ON BEHALF OF THE REGISTRANT AND IN THE CAPACITIES
AND ON THE DATES INDICATED



|SIGNATURE            |  | TITLE                                   |  | DATE          
|-------------------- |  | --------------------------------------- |  | --------------
|                     |  |                                         |  |               
|/s/ Igor Gorodnitsky |  | President; Member of Board of Directors |  | April 28, 2017
|Igor Gorodnitsky     |  | (Principal Executive Officer)           |  |               
|                     |  |                                         |  |               
|                     |  |                                         |  |               
|/s/ N. Voloshin      |  | Chief Financial Officer                 |  | April 28, 2017
|N. Voloshin          |  | (Principal Financial Officer)           |  |               
|                     |  |                                         |  |               



31